We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sky Capital Enterprises announced that its 40 percent owned subsidiary Advanced
Spinal Technologies (AST) has completed and filed an application with the FDA
seeking approval of the use in the U.S. of the pamm3 MicroManipulator to be
marketed in the U.S. as the Technology Assisted Micro-manipulation and Reflex
Stimulator -- an instrument intended for adjustment, mobilization, or manipulation
of the musculoskeletal joints of the spine.
Illumina announced that it plans to release, by June 2006, a whole-genome microarray
offering that will utilize the company's new Infinium assay and enable researchers
to genotype one million Single Nucleotide Polymorphisms (SNPs) on a pair of
Sentrix BeadChips.
Gen-Probe, which develops, makes and markets nucleic acid tests, said its Aptima
assay for the detection of Neisseria gonorrhoeae (GC) received marketing clearance
from the FDA.
Aviva Systems Biology announced the launch of the ChIP-GLAS (Chromatin Immunoprecipitation-Guided
Ligation And Selection) system, the core of its Gene Regulation Elements Mapping
and Analysis (GREMA) Technology.
Huntleigh Healthcare announced a new three-year contract with Novation, the
supply company of VHA and the University HealthSystem Consortium, effective
April 1. The agreement covers Huntleigh's Flowtron Line of Intermittent Pneumatic
Compression Devices for the prevention of deep vein thrombosis.
Akers Biosciences announced the company has received $2.5 million, the principal
amount of promissory notes convertible into shares of the company's common stock.
Coronado Industries, the manufacturers of unique proprietary pneumatic devices
for the non-invasive treatment of glaucoma through its wholly owned subsidiary,
Ophthalmic International, announced they have recently entered into a services
agreement with ClinReg Consulting Services of Irvine, Calif., to assist the
company in achieving the regulatory approval necessary to allow the introduction
of Coronado's PNT (Pneumatic Trabeculoplasty) technology in the U.S.
ChondroGene reported that it has received a contribution from National Research
Council's Industrial Research Assistance Program (NRC-IRAP) in support of the
development of a blood-based molecular diagnostic assay that will be able to
detect early, asymptomatic osteoarthritis as well as stage the severity of the
disease.
RheoGene announced that it has granted a nonexclusive
worldwide license to Genomatix to produce custom DNA vectors that incorporate
RheoGene's RheoSwitch inducible gene regulation technology.